Online resource aims to promote better MSK health to prevent against later problems

Online resource aims to promote better MSK health to prevent against later problems

December 7 2017 A new online resource addressing productive healthy ageing and musculoskeletal...

Public Accounts Committee calls for ‘end to complacency’ over clinical negligence costs

Public Accounts Committee calls for ‘end to complacency’ over clinical negligence costs

December 5 2017 MPs have said “bold action” is required “to address impact of...

Department of Health sets out information on plans for GP indemnity scheme

Department of Health sets out information on plans for GP indemnity scheme

December 4 2017 The Department of Health has set out how it proposes to develop the state-backed...

Concerns raised that new NICE asthma guidelines conflict with BTS/SIGN approach

Concerns raised that new NICE asthma guidelines conflict with BTS/SIGN approach

December 1 2017 NICE new guidelines on asthma, addressing diagnosis, monitoring and the...

Bowel cancer screening uptake falls in England

Bowel cancer screening uptake falls in England

November 28 2017 Public Health England is warning that over two fifths of eligible adults are not...

  • Online resource aims to promote better MSK health to prevent against later problems

    Online resource aims to promote better MSK health to prevent against later problems

    Thursday, 07 December 2017 17:40
  • Public Accounts Committee calls for ‘end to complacency’ over clinical negligence costs

    Public Accounts Committee calls for ‘end to complacency’ over clinical negligence costs

    Tuesday, 05 December 2017 11:01
  • Department of Health sets out information on plans for GP indemnity scheme

    Department of Health sets out information on plans for GP indemnity scheme

    Monday, 04 December 2017 15:26
  • Concerns raised that new NICE asthma guidelines conflict with BTS/SIGN approach

    Concerns raised that new NICE asthma guidelines conflict with BTS/SIGN approach

    Friday, 01 December 2017 10:38
  • Bowel cancer screening uptake falls in England

    Bowel cancer screening uptake falls in England

    Tuesday, 28 November 2017 09:56

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Professional News

December 13 2017 Women using hormonal contraceptives are exposed to a 20% increased risk of developing breast cancer, a 17-year-long study has shown. The relative risk is considered small, however,...
December 10 2015 A doctor may find themselves the subject of an investigation at any time in their career, from medical students to trainee doctors, GPs or consultants. Whether it’s an issue...